Minato-ku, Tokyo, Japan, January 24 2023 — Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced

Using digital biomarkers to assess patients’ sleep and daytime activity Research could result in a more multifaceted and higher-quality approach to evaluating treatment efficacy Sleep

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative

– Initiating digital transformation (DX) in clinical trial and joint research utilizing real-world data – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director

– Introducing digital transformation (DX) for monitoring work and reducing new drug development costs – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo, President and

– a fact-finding survey of patients with sleep disorders to be conducted as a first step – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo,

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical company focused on the development and

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a biopharmaceutical company…

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical …

Aculys Pharma, Inc. (Aculys Pharma), a new biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields…